Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
Mela Osorio MJ, Moiraghi B, Osycka MV, Pavlovsky MA, Varela AI, Bendek Del Prete GE, Tosin MF, Pérez MA, Riva ME, Berrios RR, Fernández I, Sackmann Massa F, Giere I, Sighel C, Pavlovsky C. Mela Osorio MJ, et al. Among authors: giere i. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):158-164. doi: 10.1016/j.clml.2023.10.008. Epub 2023 Oct 26. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37973457
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C, Giere I, Moiraghi B, Pavlovsky MA, Aranguren PN, García J, Fernandez I, Bengió R, Milone J, Labanca V, Uriarte R, Lombardi V, Reinoso FG, Magariños AE, Martinez L, Murro H, Lastiri F, Pavlovsky S. Pavlovsky C, et al. Among authors: giere i. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):280-5. doi: 10.1016/j.clml.2011.03.016. Epub 2011 Apr 20. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21658656 Clinical Trial.
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M, Boquimpani C, Centrone R, Conchon M, Delgado N, Funke V, Giere I, Luise I, Meillon L, Moiraghi B, Navarro JR, Pilleux L, Prado AI, Undurraga S, Cortes J. Pavlovsky C, et al. Among authors: giere i. Blood Adv. 2021 Dec 14;5(23):4855-4863. doi: 10.1182/bloodadvances.2020003235. Blood Adv. 2021. PMID: 34438444 Free PMC article.
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, Bianchini M. Pavlovsky C, et al. Among authors: giere i. J Hematol Oncol. 2023 Apr 29;16(1):43. doi: 10.1186/s13045-023-01440-6. J Hematol Oncol. 2023. PMID: 37120577 Free PMC article.
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB, Vasconcelos Cordoba B, Pavlovsky C, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, García de Labanca A, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Levy EM, Bianchini M. Sanchez MB, et al. Among authors: giere i. Front Immunol. 2023 Sep 25;14:1241600. doi: 10.3389/fimmu.2023.1241600. eCollection 2023. Front Immunol. 2023. PMID: 37818372 Free PMC article. Clinical Trial.
17 results